Other symptoms of advanced stage Parkinson's disease;Les autres symptomes de la phase evoluee de la maladie de Parkinson

Revue Neurologique

Volumn 156, Issue SUPPL. 2 BIS, 2000, Pages 165-173

  Pollak, P ^b   Tranchant, C ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY; AUTONOMIC DYSFUNCTION; CONFERENCE PAPER; DEMENTIA; DEPRESSION; DETRUSOR DYSSYNERGIA; DYSAUTONOMIA; HALLUCINATION; HUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; SLEEP DISORDER; SYMPTOMATOLOGY;

ANTIPARKINSON AGENTS; ANXIETY; DEPRESSION; HALLUCINATIONS; HUMANS; HYPOTENSION, ORTHOSTATIC; PARKINSON DISEASE; SLEEP DISORDERS; URINARY INCONTINENCE;

EID: 0033913462     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (65)

1. ACKERMANN H, GRONE BF, HOCH G, SCHONLE PW. (1993). Speech freezing in Parkinson's disease: a kinematic analysis of orofacial movements by means of electromagnetic articulography. Folia Phoniatr (Basel), 45: 84-89.
2. AHMAD RAS, WATSON RDS. (1990). Treatment of postural hypotension. A review. Drugs, 39: 74-85.
3. AITA JF. (1982). Why patients with Parkinson's disease fall. JAMA, 247: 515-516.
4. ALBANESE A, MARIA G, BENTIVOGLIO AR, BRISINDA G, CASSETA E, TONALI P. (1997). Bolulinum toxin in the treatment of chronic constipation in Parkinson's disease. Europ J Neurol, 4: 81-83.
5. ALI GB, WALLACE KL, SCHWARTZ R, DECARLE DJ, ZAGAMI AS, COOK IJ. (1996). Mechanisms of oral-pharyngeal dysphagia in patients with Parkinson's disease. Gastroenterology, 110: 383-392.
6. AMBANI LM, VAN WOERT MH. (1973). Start hesitation-a side effect of long-term levodopa therapy. N Engl J Med, 288: 1113-1115.
7. ARANDA B. (1993). Les troubles vésico-sphinctériens de la maladie de Parkinson. Rev Neurol, 149: 476-480.
8. BLIN J, DUBOIS B, BONNET AM, VIDAILHET M, BRANDABUR M, AGID Y. (1991). Does ageing aggravate parkinsonian disability? J Neurol Neurosurg Psychiatry, 54: 780-782.
9. BONNET AM, LORIA Y, SAINT-HILAIRE MH, LHERMITTE F, AGID Y. (1987). Does long-term aggravation of Parkinson's disease result from nondoparninergic lesions? Neurology, 37: 1539-1542.
10. BONNET AM, PICHON J, VIDAILHET M, GOUIDER-KHOUJA N, ROBAIN G, PERRIGOT M, AGID Y. (1997). Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects. Mov Dis, 12: 509-513.
11. BROWN RG, MARSDEN CD. (1990). Cognitive function in Parkinson's disease: from descript on to theory. Trends Neurosci, 13: 21-29.
12. COMELLA CL, NARDINE TM, DIEDERICH NJ, STEBBINS GT. (1998). Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology, 51: 526-529.
13. COOPER JA, SAGAR HJ, JORDAN N, HARVEY NS, SULLIVAN EV. (1991). Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain, 114: 2095-2122.
14. DOONEIEF G, MlRABELLO E, BELL K, MARDER K, STERN Y, MAYEUX R. (1992). An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol, 49: 305-307.
15. DOUYON R, SERBY M, KLUTCHKO B, ROTROSEN J. (1989). ECT and Parkinson's disease revisited: a "naturalistic" study [see comments]. Am J Psychiatry, 146: 1451-1455.
16. EDWARDS LL, GUIGLEY EMM, PFEIFFER RF. (1992). Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology, 42: 726-732.
17. FACTOR SA, MOLHO ES, PODSKALNY GD, BROWN D. (1995). Parkinson's disease: drug-induced psychiatric states. Adv Neurol, 65: 115-138.
18. FAHN S. (1995). The freezing phenomenon in parkinsonism. Adv Neurol, 67: 53-63.
19. FERNANDEZ HH, FRIEDMAN JH, JACQUES C, ROSENFELD M. (1999). Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord, 14: 484-487.
20. FRIEDMAN JH. (1991). The management of the levodopa psychoses. Clin Neuropharmacol, 14: 283-295.
21. FRIEDMAN JH, FEINBERG SS, FELDMAN RG. (1985). A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. JAMA, 254: 2792-2795.
22. FRUCHT S, ROGERS JD, GREENE PE, GORDON MF, FAHN S. (1999). Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology, 52: 1908-1910.
23. GENTIL M, GARCIA-RUIZ P, POLLAK P, BENABID AL. (1999). Effect of stimulation of the subthalamic nucleus on oral control of patients with parkinsonism. J Neurol Neurosurg Psychiatry, 67: 329-333.
24. GENTIL M, POLLAK P, PERRET J. (1995). La dysarthrie parkinsonienne. Rev Neurol (Paris), 151: 105-112.
25. GILADI N, KAO R, FAHN S. (1997). Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord, 12: 302-305.
26. GOETZ CG, STEBBINS GT. (1993). Risk factors for nursing home placement in advanced Parkinson's disease. Neurology, 43: 2227-2229.
27. GOETZ CG, STEBBINS GT. (1995). Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology, 45: 669-671.
28. HILLEN ME, SAGE JI. (1996). Nonmotor fluctuations in patients with Parkinson's disease. Neurology, 47: 1180-1183.
29. LIPE H, LONGSTRETH WT, BIRD TD, LINDE M. (1990). Sexual function in married men with Parkinson's disease compared to married men with arthritis. Neurology, 40: 1347-1349.
30. MALLY J, STONE TW. (1999). Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. J Neurol Sci, 162: 179-184.
31. MANO Y, NAKAMURO T, TAKAYANAGI T, MAYER RF. (1994). Sweat function in Parkinson's disease. J. Neurol, 241: 573-576.
32. MATHERS SE, KEMPSTER PA, LAW PJ, FRANKEL JP, BARTRAM CI, LEES AJ, STERN GM, SWASH M. (1989). Anal sphincter dysfunction in Parkinson's disease. Arch Neurol, 46: 1061-1064.
33. MATHERS SE, KEMPSTER PA, SWASH M, LEES AJ. (1988). Constipation and paradoxical puborectallis contraction in animus and parkinson's disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry, 51: 1503-1507.
34. MAYEUX R, DENARO J, HEMENEGILDO N, MARDER K, TANG MX, COTE LJ, STERN Y. (1992). A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol, 49: 492-497.
35. MCCANCE-KATZ EF, MAREK KL, PRICE LH (1992). Serotonergic dysfunction in depression associated with Parkinson's disease [see comments]. Neurology, 42: 1813-1814.
36. MENZA MA, SAGE J, MARSHALL E, CODY R, DUVOISIN R. (1990). Mood changes and "on-off" phenomena in Parkinson's disease [see comments]. Mov Disord, 5: 148-151.
37. MOLHO ES, FACTOR SA. (1999). Worsening of motor features of parkinsonism with olanzapine. Mov Disord, 14: 1014-1016.
38. NAUSIEDA PA, LEO GJ, CHESNEY C. (1994). A comparison of conventional and Sinemet CR on the sleep of parkinsonian patients. Neurology, 44 (Suppl 2): A219.
39. OLANOW CW, KOLLER WC (1998). An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines.American Academy of Neurology. Neurology, 50: S1-57.
40. PAL PK, CALNE DB, SAMII A, FLEMING JAE. (1999). A review of normal sleep and its disturbances in Parkinson's disease. Parkinsonism and Related Disorders, 5: 1-17.
41. PAL PK, CALNE DB, CALNE S, TSUI JKC. (2000). Botulinum toxin A as treatment for drooling salivia inPD. Neurology, 54: 244-247.
42. PAPPERT EJ, GOETZ CG, NIEDERMAN FG, RAMAN R, LEURGANS S. (1999). Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord, 14: 117-121.
43. PERRY RJ, HODGES JR. (1996). Spectrum of memory dysfunction in degenerative disease. Curr Opin Neurol, 9: 281-285.
44. QUAGLIERI CE, CELESIA GG. (1977). Effect of thalamotomy and levodopa therapy on the speech of Parkinson patients. Eur Neurol, 15: 34-39.
45. RICH SS, FRIEDMAN JH, OTT BR. (1995). Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry, 56: 556-559.
46. RICHARD IH, KURLAN R. (1997). A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology, 49: 1168-1170.
47. RICHARD IH, KURLAN R, TANNER C, FACTOR S, HUBBLE J, SUCHOWERSKY O, WATERS C. (1997). Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology, 48: 1070-1077.
48. SANO M, STERN Y, WILLIAMS J, COTE L, ROSENSTEIN R, MAYEUX R. (1989). Coexisting dementia and depression in Parkinson's disease. Arch Neurol, 46: 1284-1286.
49. SCHENCK CH, MAHOWALD MW. (1990). Polysomnographic, neurologic, psychiatric, and clinical outcome report on 70 consecutive cases with REM sleep behavior disorder (RBD): sustained clonazepam efficacy in 89,5p.100 of 57 treated patients. Clev Clin J Med, 57 (suppl): S9-S23.
50. SENARD JM, RAI S, LAPEYRE-MESTRE M, BREFEL C, RASCOL O, RASCOL A, MONTASTRUC JL. (1997). Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry, 63: 584-589.
51. STEIN MB, HEUSER IJ, JUNCOS JL, UHDE TW. (1990). Anxiety disorders in patients with Parkinson's disease [see comments]. Am J Psychiatry, 147: 217-220.
52. STERN GM, LANDER CM, LEES AJ. (1980). Akinetic freezing and trick movements in Parkinson's disease. J Neurol Transm Suppl: 137-141.
53. STEUR EN. (1993). Increase of Parkinson disability after fluoxetine medication. Neurology, 43: 211-213.
54. STOCCHI F, BARBATO L, NORDERA G, BERARDELLI A, RUGGIERI S. (1998). Sleep disorders in Parkinson's disease. J Neurol, 245: 15-18.
55. STOCCHI F, CARBONE A, INGHILLERI M, MONGE A, RUGGIERI S, BERARDELLI A, MANFREDI M. (1997). Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry, 62: 507-511.
56. SUCHOWERSKY O, FURTADO S., ROHS G. (1995). Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord, 10: 337-340.
57. SUCHOWEHSKY O, DEVRIES JD. (1990). Interaction of fluoxetine and selegiline [letter]. Can J Psychiatry, 35: 571-572.
58. THE FRENCH CLOZAPINE PARKINSON STUDY GROUP. (1999). Clozapine in drug-induced psychosis in Parkinson's disease. Lancet, 353: 2041-2042.
59. THE PARKINSON STUDY GROUP. (1999). Low-dose Clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med, 340: 757-763.
60. TISON F, DARTIGUES JF, AURIACOMBE S, LETENNEUR L, BOLLER F, ALPEROVITCH A. (1995). Dementia in Parkinson's disease: a population-based study in ambulatory and institutionalized individuals. Neurology, 45: 705-708.
61. TROSCH RM, FRIEDMAN JH, LANNON MC, PAHWA R, SMITH D, SEEBERGER LC, O'BRIEN CF, LEWITT PA, KOLLER WC. (1998). Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord, 13: 377-382.
62. UITTI RJ, TANNER CM, RAJPUT AH, GOETZ CG, KLAWANS HL, THIESSEN B. (1989). Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol, 12: 375-383.
63. VAN DIJK JG, HAAN J, ZWINDERMAN K, KREMER B, VAN HILTEN BJ, ROOS RAC. (1993). Autonomic nervous system dysfunction in Parkinson's disease: relationships with age, medication, duration, and severity. J Neurol Neurosurg Psychiatry, 56: 1090-1095.
64. VAZOUEZ A, JIMENEZ-JIMENEZ FJ, GARCIA-RUIZ P, GARCIA-URRA D. (1993). "Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy. Acta Neurol Scand, 87: 14-18.
65. WALTERS AS and THE INTERNATIONAL RLS STUDY GROUP. (1995). Toward a better definition of the restless legs syndrome. Mov Disord, 10: 634-642.